Differential effects of serotonin (5-HT) lesions and synthesis blockade on neuropeptide-Y immunoreactivity and 5-HT1A, 5-HT1B/1D and 5-HT2A/2C receptor binding sites in the rat cerebral cortex

Brain Res. 1998 Jun 8;795(1-2):264-76. doi: 10.1016/s0006-8993(98)00316-3.

Abstract

The present study was aimed at comparing the effects of serotonin (5-HT) synthesis blockade using chronic administration of p-chlorophenylalanine (PCPA) and 5,7-dihydroxytryptamine injections of variable volume (3 vs. 6 microl) on the density of NPY immunoreactive (Ir) neurons and binding of [3H]8-OH-DPAT, S-CM-G[125I]TNH2 and [125I]DOI to 5-HT1A, 5-HT1B/1D, and 5-HT2A/2C receptors in rat cortical regions. Three weeks after large but partial (89% depletion in 5-HT tissue concentration) lesions of 5-HT neurons no changes in neither NPY immunoreactivity nor 5-HT receptor binding were detected. The complete 5,7-DHT lesions produced increases in the number of NPY-Ir neurons in the upper regions of the cingular (134%), frontal (140%) and parietal cortex (48%) and corresponding decreases in 5-HT2A/2C binding (16-26%). No changes in 5-HT1A and 5-HT1B/1D binding were observed after lesions of this kind. After PCPA treatment, decreases in NPY-Ir neurons density (22-40%) and increases in 5-HT1A and 5-HT1B/1D receptor binding sites (20-50%) were distributed in both upper and deeper cortical regions. The lack of effect of the partial lesion suggests that spared 5-HT neurons may exert compensatory mechanisms up to a large extent. The changes in NPY immunoreactivity and 5-HT2A/2C binding detected in the upper regions of the cortex after complete 5-HT lesions probably result from local cellular rearrangements, whereas blocking 5-HT synthesis has more widespread influence on NPY neurons and on 5-HT1A and 5-HT1B/1D receptor subtypes. Moreover, decreases in DOPAC concentrations detected only after complete lesions suggest that the involvement of catecholaminergic transmission may also differentiate 5,7-DHT and PCPA treatments. Altogether, these data suggest that different receptor subtypes might be involved in 5-HT-NPY relationships.

MeSH terms

  • 3,4-Dihydroxyphenylacetic Acid / metabolism
  • 5,7-Dihydroxytryptamine / pharmacology
  • 8-Hydroxy-2-(di-n-propylamino)tetralin / pharmacology
  • Amphetamines / pharmacology
  • Animals
  • Binding, Competitive / physiology
  • Cerebral Cortex / chemistry*
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / metabolism*
  • Dipeptides / pharmacology
  • Dopamine / metabolism
  • Female
  • Fenclonine / pharmacology
  • Iodine Radioisotopes
  • Neuronal Plasticity / physiology
  • Neuropeptide Y / analysis*
  • Neuropeptide Y / immunology
  • Rats
  • Rats, Wistar
  • Receptor, Serotonin, 5-HT1D
  • Receptor, Serotonin, 5-HT2A
  • Receptors, Serotonin / analysis*
  • Receptors, Serotonin / immunology
  • Receptors, Serotonin, 5-HT1
  • Serotonin / analogs & derivatives
  • Serotonin / biosynthesis*
  • Serotonin / pharmacology
  • Serotonin Agents / pharmacology
  • Tritium

Substances

  • Amphetamines
  • Dipeptides
  • Iodine Radioisotopes
  • Neuropeptide Y
  • Receptor, Serotonin, 5-HT1D
  • Receptor, Serotonin, 5-HT2A
  • Receptors, Serotonin
  • Receptors, Serotonin, 5-HT1
  • Serotonin Agents
  • Tritium
  • 3,4-Dihydroxyphenylacetic Acid
  • serotonin-O-carboxymethyl-Gly-Tyr
  • 5,7-Dihydroxytryptamine
  • Serotonin
  • 8-Hydroxy-2-(di-n-propylamino)tetralin
  • 4-iodo-2,5-dimethoxyphenylisopropylamine
  • Fenclonine
  • Dopamine